Here’s something that caught our attention at ASCRS this month. A retina specialist from a three-physician practice in Charlotte pulled us aside and asked, unprompted, “What do you know about Meridian?” Six months ago, almost nobody outside of European ophthalmic circles was asking that question. Now we’re hearing it regularly.
That shift didn’t happen by accident. Meridian Medical, the Swiss laser manufacturer, spent the last two years executing a deliberate US market entry—landing FDA clearances for its entire Merilas retinal platform in September 2023, followed by the MR Q anterior segment family in January 2024. The result is one of the most complete ophthalmic laser portfolios available from a single manufacturer. Four wavelengths. Eleven product configurations. And a proprietary tissue-sparing technology called Shortpulse that’s worth your attention.
We’ve spent the last several months looking closely at the Meridian lineup. Here’s what you need to know.
The Merilas Platform: Three Wavelengths, One Interface
Start with the retinal side, because that’s where Meridian’s clinical argument is strongest.
The Merilas family covers the three wavelengths that matter for retinal work: 532nm green, 577nm yellow, and 810nm infrared diode. Each is available with Meridian’s Shortpulse capability—their term for subthreshold micropulse delivery—meaning you can treat tissue without visible burns or permanent scarring. The 532 SP and 577 SP share identical parameter ranges: 50–2,500mW output, pulse durations from 10–9,500 microseconds in Shortpulse mode, and CW capability from 1–5,000ms. From a practical standpoint, if you learn one system, you’ve learned them all.
The 577nm yellow variant deserves specific attention. That wavelength sits at peak oxyhemoglobin absorption while showing negligible uptake by macular xanthophyll pigments—which is a technical way of saying it’s inherently safer for macular and perimacular work. Clinical data from a Wills Eye Hospital randomized crossover study confirmed comparable-to-reduced patient pain scores versus 532nm green during PRP. If you’re doing significant retinal laser volume, particularly diabetic retinopathy and macular edema cases, the 577nm makes the stronger clinical case.
Worth noting: the entire Merilas family uses thermoelectric cooling. No fan. No ventilation slots. The units are hermetically sealed and weigh just 7kg—about 15 pounds. That’s compact enough to fit comfortably in an ASC procedure room, and the dust-free design means one less maintenance variable.
Pattern Scanning at Speed
Meridian’s multispot systems came through the 2019 acquisition of Valon Lasers in Finland, and they’re built around high-speed galvanometric scanners. The flagship TT 577 integrates everything—laser, electronics, computer—into the table itself. Two features stand out.
First, Valon’s patented Information Projection technology projects your treatment parameters directly onto the retina during the procedure. You’re not glancing at a separate screen. Second, the Smart Wheel controller lets you adjust all variables without removing your eyes from the oculars. For a high-volume retina practice doing 20+ PRP sessions a week, those details translate directly into workflow efficiency. Meridian claims full PRP in under six minutes. That tracks with what we’ve heard from early adopters.
The MR Q Family: Where Things Get Interesting
The anterior segment lineup is where Meridian has something genuinely different.
The standard MR Q is a Nd:YAG (1064nm) with five-step magnification, tested to over 600,000 exposures per laser cavity, and featuring an electronically controlled digital offset that auto-resets to 100 micrometers posterior after each treatment. That last detail matters more than it sounds—it’s a safety guard against accidental IOL pitting during capsulotomy, and it’s the kind of design choice that reflects genuine clinical understanding.
The MR Q SLT combines Nd:YAG and selective laser trabeculoplasty (532nm) in a single dual-laser module. One platform for capsulotomy, iridotomy, and SLT. For a practice adding SLT volume—and given the LiGHT trial’s 6-year data showing 69.8% of SLT-treated eyes maintained drop-free IOP control, you probably should be—this avoids a second capital purchase.
But the real standout is the MR Q Supine. It’s the only Nd:YAG laser on the market designed specifically for supine-position treatment. Tiltable Haag-Streit binoculars from 0 to 210 degrees, electronically controlled laser movement, auto-locking wheels. If you treat pediatric ROP patients or adults who can’t sit at a slit lamp, this fills a gap that nobody else is filling right now.
The Haag-Streit Partnership and What It Signals
Meridian is the only laser company with an integrated Haag-Streit slit lamp partnership. That’s not a small detail. Haag-Streit’s optical quality is well established, and the integration goes beyond bolting a laser onto someone else’s lamp. Three adapter configurations are available—the BQ integrated, a universal Haag-Streit-style adapter, and a Zeiss-compatible option—so the system fits your existing exam lane setup.
From a total-cost-of-ownership perspective, that kind of integration tends to mean fewer compatibility headaches and simpler service calls. We’ve seen enough practices struggle with multi-vendor slit lamp and laser combinations to appreciate the value.
Where Meridian Fits in Your Evaluation
Let’s be direct about the competitive landscape. You’re evaluating Meridian against established players—IRIDEX with its IQ 577 and PASCAL Synthesis, Lumenis, Lumibird, LIGHTMED, Topcon. Each has strengths.
Meridian’s argument rests on three pillars. First, breadth: four wavelengths and eleven configurations from a single manufacturer, with a shared interface philosophy across the product line. Second, the Shortpulse subthreshold technology available on every retinal platform, not just a premium tier. Third, Swiss-European vertical integration—R&D, manufacturing, and service across three facilities in Switzerland, Finland, and Slovenia.
The honest tradeoff? Meridian is newer to the US market. Their distribution network—Bell Ophthalmic east of the Mississippi, Pacific Eye Instruments, US Ophthalmic, and Shaffer Vision Solutions—is still maturing. Field service coverage isn’t as deep as what you’d get from IRIDEX or Lumenis today. For a practice that values rapid on-site service response above all else, that’s a real consideration. For a practice prioritizing clinical capability and long-term platform consolidation, Meridian deserves a serious look.
What’s Coming Next
One more thing worth tracking. Meridian is developing Selective Retinal Treatment (SRT) in collaboration with Bern University—a technology that provides real-time feedback on retinal response and energy delivery during treatment. If that reaches commercial availability, it would represent a meaningful step toward closed-loop, feedback-controlled laser therapy. The company hasn’t announced a timeline, but they’re presenting at every major meeting in 2026—ASCRS, SFO, ESCRS, EURETINA, AAO—and we expect to see clinical data emerge over the next 12 to 18 months.
The ophthalmic laser market hasn’t had a genuinely new competitive entrant in years. Meridian isn’t exactly new—they’ve been building lasers since before most of us were born—but their US presence is. And for a market that’s been dominated by the same handful of players, a well-funded Swiss manufacturer with a complete product line and something to prove is exactly the kind of competitive pressure that tends to benefit buyers.
Keep them on your list.
Eye Care Technologies helps practices evaluate, acquire, and maintain ophthalmic laser platforms. If you’re considering a technology transition, we’d welcome the conversation. www.EyeCareTechnologies.com
